Histone deacetylase inhibitors suppress CXCR4-mediated dendritic cell migration by regulation of maturation process

Cellular Immunology

Volumn 284, Issue 1-2, 2013, Pages 139-145

  Kim, Young Hoon ^a   Han, Sang Bae ^a   Lee, Jae Kwon ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Cell migration; CXCR4; Dendritic cell; HDAC inhibitor; Inflammation; SDF 1

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; HISTONE DEACETYLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HISTONE ACETYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

CELL MIGRATION; CXCR4; DENDRITIC CELL; HDAC INHIBITOR; INFLAMMATION; SDF-1Α;

ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; CELL SURVIVAL; DENDRITIC CELLS; HISTONE DEACETYLASE INHIBITORS; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTORS, CXCR4;

EID: 84883012792     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.07.014     Document Type: Article

References (47)

1. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
2. Huang L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J. Cell. Physiol. 2006, 209:611-616.
3. Mishra N., Reilly C.M., Brown D.R., Ruiz P., Gilkeson G.S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 2003, 111:539-552.
4. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., Dona G., Fossati G., Sozzani S., Azam T., Bufler P., Fantuzzi G., Goncharov I., Kim S.H., Pomerantz B.J., Reznikov L.L., Siegmund B., Dinarello C.A., Mascagni P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. USA 2002, 99:2995-3000.
5. Reddy P., Teshima T., Kukuruga M., Ordemann R., Liu C., Lowler K., Ferrara J.L. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 2001, 194:1433-1440.
6. Chung Y.L., Lee M.Y., Wang A.J., Yao L.F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 2003, 8:707-717.
7. Nishida K., Komiyama T., Miyazawa S., Shen Z.N., Furumatsu T., Doi H., Yoshida A., Yamana J., Yamamura M., Ninomiya Y., Inoue H., Asahara H. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 2004, 50:3365-3376.
8. Reilly C.M., Mishra N., Miller J.M., Joshi D., Ruiz P., Richon V.M., Marks P.A., Gilkeson G.S. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J. Immunol. 2004, 173:4171-4178.
9. Kim E.S., Lee J.K. Histone deacetylase inhibitors decrease the antigen presenting activity of murine bone marrow derived dendritic cells. Cell. Immunol. 2010, 262:52-57.
10. Choi Y., Park S.K., Kim H.M., Kang J.S., Yoon Y.D., Han S.B., Han J.W., Yang J.S., Han G. Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model. Exp. Mol. Med. 2008, 40:574-581.
11. Morgan M.M., Clayton C.C., Heinricher M.M. Dissociation of hyperalgesia from fever following intracerebroventricular administration of interleukin-1beta in the rat. Brain Res. 2004, 1022:96-100.
12. Sarafi M.N., Garcia-Zepeda E.A., MacLean J.A., Charo I.F., Luster A.D. Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1. J. Exp. Med. 1997, 185:99-109.
13. Nakahara T., Moroi Y., Uchi H., Furue M. Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement. J. Dermatol. Sci. 2006, 42:1-11.
14. Quah B.J., O'Neill H.C. Maturation of function in dendritic cells for tolerance and immunity. J. Cell. Mol. Med. 2005, 9:643-654.
15. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 2005, 23:975-1028.
16. Kadowaki N., Antonenko S., Ho S., Rissoan M.C., Soumelis V., Porcelli S.A., Lanier L.L., Liu Y.J. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J. Exp. Med. 2001, 193:1221-1226.
17. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 1995, 182:389-400.
18. Triantaphyllopoulos K.A., Williams R.O., Tailor H., Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum. 1999, 42:90-99.
19. Chen Y.W., Shi R., Geraci N., Shrestha S., Gordish-Dressman H., Pachman L.M. Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol. 2008, 9:43.
20. Brogdon J.L., Xu Y., Szabo S.J., An S., Buxton F., Cohen D., Huang Q. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007, 109:1123-1130.
21. Notarbartolo M., Poma P., Perri D., Dusonchet L., Cervello M., D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett. 2005, 224:53-65.
22. Sarkar S., Fox D.A. Dendritic cells in rheumatoid arthritis. Front. Biosci. 2005, 10:656-665.
23. Zhuang H., Narain S., Sobel E., Lee P.Y., Nacionales D.C., Kelly K.M., Richards H.B., Segal M., Stewart C., Satoh M., Reeves W.H. Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin. Immunol. 2005, 117:238-250.
24. Sallusto F., Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol. Rev. 2000, 177:134-140.
25. Forster R., Schubel A., Breitfeld D., Kremmer E., Renner-Muller I., Wolf E., Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999, 99:23-33.
26. Sallusto F., Palermo B., Lenig D., Miettinen M., Matikainen S., Julkunen I., Forster R., Burgstahler R., Lipp M., Lanzavecchia A. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur. J. Immunol. 1999, 29:1617-1625.
27. Vecchi A., Massimiliano L., Ramponi S., Luini W., Bernasconi S., Bonecchi R., Allavena P., Parmentier M., Mantovani A., Sozzani S. Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. J. Leukoc. Biol. 1999, 66:489-494.
28. Luster A.D., Weinshank R.L., Feinman R., Ravetch J.V. Molecular and biochemical characterization of a novel gamma-interferon-inducible protein. J. Biol. Chem. 1988, 263:12036-12043.
29. Proudfoot A.E. Chemokine receptors: multifaceted therapeutic targets. Nat. Rev. Immunol. 2002, 2:106-115.
30. De Smedt T., Pajak B., Muraille E., Lespagnard L., Heinen E., De Baetselier P., Urbain J., Leo O., Moser M. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. Exp. Med. 1996, 184:1413-1424.
31. Stockwin L.H., McGonagle D., Martin I.G., Blair G.E. Dendritic cells: immunological sentinels with a central role in health and disease. Immunol. Cell Biol. 2000, 78:91-102.
32. Yanagihara S., Komura E., Nagafune J., Watarai H., Yamaguchi Y. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J. Immunol. 1998, 161:3096-3102.
33. Alvarez D., Vollmann E.H., von Andrian U.H. Mechanisms and consequences of dendritic cell migration. Immunity 2008, 29:325-342.
34. Crazzolara R., Johrer K., Johnstone R.W., Greil R., Kofler R., Meister B., Bernhard D. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br. J. Haematol. 2002, 119:965-969.
35. Stamatopoulos B., Meuleman N., De Bruyn C., Delforge A., Bron D., Lagneaux L. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica 2010, 95:1136-1143.
36. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912.
37. Bian Z.M., Elner S.G., Yoshida A., Elner V.M. Human RPE-monocyte co-culture induces chemokine gene expression through activation of MAPK and NIK cascade. Exp. Eye Res. 2003, 76:573-583.
38. Iijima N., Yanagawa Y., Clingan J.M., Onoe K. CCR7-mediated c-Jun N-terminal kinase activation regulates cell migration in mature dendritic cells. Int. Immunol. 2005, 17:1201-1212.
39. Li G., Basu S., Han M.K., Kim Y.J., Broxmeyer H.E. Influence of ERK activation on decreased chemotaxis of mature human cord blood monocyte-derived dendritic cells to CCL19 and CXCL12. Blood 2007, 109:3173-3176.
40. Anand A.R., Prasad A., Bradley R.R., Deol Y.S., Nagaraja T., Ren X., Terwilliger E.F., Ganju R.K. HIV-1 gp120-induced migration of dendritic cells is regulated by a novel kinase cascade involving Pyk2, p38 MAP kinase, and LSP1. Blood 2009, 114:3588-3600.
41. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265:17174-17179.
42. Guan R.J., Ford H.L., Fu Y., Li Y., Shaw L.M., Pardee A.B. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res. 2000, 60:749-755.
43. Richon V.M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., Civoli F., Breslow R., Rifkind R.A., Marks P.A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA 1996, 93:5705-5708.
44. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390.
45. Nencioni A., Beck J., Werth D., Grunebach F., Patrone F., Ballestrero A., Brossart P. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer Res. 2007, 13:3933-3941.
46. Wang B., Morinobu A., Horiuchi M., Liu J., Kumagai S. Butyrate inhibits functional differentiation of human monocyte-derived dendritic cells. Cell. Immunol. 2008, 253:54-58.
47. Misaki K., Morinobu A., Saegusa J., Kasagi S., Fujita M., Miyamoto Y., Matsuki F., Kumagai S. Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice. Arthritis Res. Ther. 2011, 13:R77.